Furthermore, with the advent of highly potent CFTR modulator treatment, pwCF born today are expected to live into their 50s and older, which presents new challenges such as menopause with post‐menopausal bone loss and higher prevalence of peripheral vascular disease and peripheral neuropathy with longer‐standing diagnosis of CFRD [32], making CFRD an additional risk factor for fractures. The gene discussed is CFTR; the disease is peripheral neuropathy.